National Cancer Institute awards Insight Genetics nearly $2M

Monies to fund continuing lung cancer test development

Insight Genetics Inc. has received $1.7 million from the National Cancer Institute to continue its research into developing two genetic mutation tests for lung cancer patients.

“We are delighted that NCI continues to recognize our company’s leadership in developing diagnostics that enable the prescription of targeted cancer therapies,” said Insight President and COO Christopher Callaghan.

Nashville-based Insight received almost $1.5 million to develop further its proprietary Insight ALK Screen that detects a specific type of lung cancer and another $200,000 to support research and development of several other specific lung cancer-related diagnostic tests.

Insight Genetics, which was founded seven years ago and is based in downtown's Cumberland Emerging Technologies incubator, earlier this year signed a deal to license its technology to a unit of GE Healthcare.